Hikma US launches generic version of Lundbeck's Onfi
By Michele Maatouk
Date: Monday 10 Dec 2018
(Sharecast News) - Hikma Pharmaceuticals' US subsidiary has launched a generic equivalent to Lundbeck's Onfi, which is used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients of two years and older.
Hikma Pharmaceuticals USA, formerly known as West-Ward Pharmaceuticals, has launched Clobazam oral suspension 2.mg/ml and Clobazam tablets, 10mg and 20mg.
Brian Hoffmann, president of Hikma's generics division, said: "We are very excited to add Clobazam oral suspension and Clobazam tablets to our product portfolio. This will be among the first generics available on the market and we are pleased to improve patients' access to this important medicine."
According to data science firm IQVIA, US sales of Clobazam oral suspension were approximately $260m, while sales of Clobazam tablets were about $601m in the 12 months to the end of September 2018.
At 1415 GMT, the shares were up 0.2% to 1,708.50p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN